Lehr, Thorsten

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin

Hanke, N., Frechen, S., Moj, D., Britz, H., Eissing, T., Wendl, T., & Lehr, T. (2018) · CPT: Pharmacometrics & Systems Pharmacology

Pharmacogenetics and Drug MetabolismPharmaceutical studies and practices

Cited by 169

Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models

Allesøe, R. L., Lundgaard, A. T., Hernández Medina, R., Aguayo-Orozco, A., Johansen, J., Nissen, J. N., Brorsson, C., Mazzoni, G., Niu, L., Biel, J. H., et al. (2023) · Nature Biotechnology

Bioinformatics and Genomic NetworksComputational Drug Discovery Methods

Cited by 111

Physiologically Based Precision Dosing Approach for Drug‐Drug‐Gene Interactions: A Simvastatin Network Analysis

Wojtyniak, J., Selzer, D., Schwab, M., & Lehr, T. (2021) · Clinical Pharmacology & Therapeutics

Pharmacogenetics and Drug MetabolismPharmaceutical studies and practices

Cited by 38

A Quantitative Systems Pharmacology Kidney Model of Diabetes Associated Renal Hyperfiltration and the Effects of SGLT Inhibitors

Balazki, P., Schaller, S., Eissing, T., & Lehr, T. (2018) · CPT: Pharmacometrics & Systems Pharmacology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 19